MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03269cam a2200325 a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GiCUC |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
210623s2021 ua d f m 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-GiCUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GiCUC |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
Deposite |
| 097 ## - Thesis Degree |
|---|
| Thesis Level |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Classification number |
Cai01.08.08.M.Sc.2021.Fa.N |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Fatma Mohamed Ahmed Elsenosy |
| 245 12 - TITLE STATEMENT |
|---|
| Title |
A novel drug design for bioavailability enhancement / |
| Statement of responsibility, etc. |
Fatma Mohamed Ahmed Elsenosy ; Supervised Ghada Ahmed Abdelbary , Ahmed Hassan , Ibrahim Elsayed |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تصميم دوائى جديد لتحفيز الأتاحة الحيوية |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Cairo : |
| Name of publisher, distributor, etc. |
Fatma Mohamed Ahmed Elsenosy , |
| Date of publication, distribution, etc. |
2021 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
94 P . : |
| Other physical details |
charts ; |
| Dimensions |
25cm |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Duloxetine (DLX) is a dual serotonin and norepinephrine reuptake inhibitor. The claimed mechanism of action of DLX is based on the specific inhibition of both serotonin and norepinephrine reuptake, while it weakly inhibits dopamine reuptake and has no significant affinity for histaminergic, dopaminergic, cholinergic or adrenergic receptors. DLX used in major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy and fibromyalgia. DLX is well absorbed after oral administration with 2 {u2013}hour lag time until absorption begins.DLX suffering from limited bioavailability ({uF0BB} 40%) due to extensive hepatic metabolism. This work aims to formulate and evaluate DLX intranasal thermoreversible cubosomal gels to enhance its bioavailability and ensure efficient brain targeting. The nasal route improves drug bioavailability by bypassing first-pass hepatic metabolism and allows direct delivery to the systemic circulation. The nasal route has privilege in brain targeting by direct drug transfer to the brain through neuronal pathway and avoidance of the blood-brain barrier. The in situ nasal gel prolongs formulation residence time and increase penetration rate with drug absorption improvement. Cubo-gels were prepared by three factors, three levels 33 central composite design to formulate 15 formulations with 5 repetitions of the center point formulation (F8). The three independent factors, lipid ratio (glycerol monooleate: glycerol tripalmitate), Pluronic F127 percent and Pluronic F68 percent. The dependant variables were particle size (PS), gelling temperature (GT), entrapment efficiency (EE %) and in-vitro release. The polydispersity index (PDI) and Zeta potential (ZP) were also measured for the prepared formulations. The PS for the prepared formulation ranged from 145.5nm to 515.9 nm, PDI ranged from 0.3 to 1, ZP ranged from 1.6 to 10.6, GT from 32oc to 80 oc, EE% from 93.1% to 99.7% and Q6 % from 20.3% to 64.5%. The cubo-gel with the highest desirability (0.88) was chosen as the optimized formula using Design Expert® software |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Additional physical form available note |
Issued also as CD |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Bioavailability enhancement |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Drug design |
| 653 #4 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Duloxetine (DLX) |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ahmed Hassan , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ghada Ahmed Abdelbary , |
| Relator term |
|
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ibrahim Elsayed , |
| Relator term |
|
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Amira |
| Reviser |
Cataloger |
| 905 ## - LOCAL DATA ELEMENT E, LDE (RLIN) |
|---|
| Cataloger |
Nazla |
| Reviser |
Revisor |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
